Verrica Pharmaceuticals (VRCA) Q4 2025 earnings summary

Executive summary

• Achieved significant transformation in 2025, doubling core product revenue, reducing costs, and expanding into new markets, with total revenue rising to $35.6M, a 370% increase year-over-year, driven by YCANTH and milestone payments.

• Implemented an optimized commercial strategy, establishing YCANTH as a standard of care for molluscum contagiosum and expanding into Europe and Japan.

• Advanced clinical programs for common warts and basal cell carcinoma, with global phase III trials underway and strong partnership with Torii in Japan.

• Selling, general, and administrative expenses decreased by over 40% year-over-year, reflecting operational efficiencies.

• No outstanding debt as of year-end 2025; cash runway extended into Q1 2027.

Financial highlights

• Q4 2025 revenue was $5.1M, up from $0.3M in Q4 2024; full-year 2025 revenue reached $35.6M, a 368%–370% increase year-over-year.

• Net YCANTH revenue for 2025 was $15.3M, with $20.3M from Torii milestone and collaboration revenue.

• Gross product margin for 2025 was 85.7%, up from 71.8% in 2024.

• GAAP net loss for 2025 was $17.9M ($1.68/share), improved from $76.6M ($14.78/share) in 2024; non-GAAP net loss was $13.2M ($1.24/share).

• Cash and equivalents at year-end 2025 were $30.1M, expected to fund operations into 2027.

Outlook and guidance

• Expect continued growth in YCANTH driven by expanded sales force, new access initiatives, and label expansion opportunities.

• Anticipate EU regulatory submission for YCANTH within 12 months, with potential for commercialization partnerships.

• Ongoing phase III trials for common warts and preparation for phase III in basal cell carcinoma, with updates on timelines and milestones expected later in 2026.

• Advancing VP-315 to Phase 3 for basal cell carcinoma in 2026.

• Regulatory alignment in the EU allows for YCANTH approval filing without additional clinical studies.